Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Dermatol Online J ; 27(3)2021 Mar 15.
Article in English | MEDLINE | ID: mdl-33865279

ABSTRACT

Scleredema adultorum of Buschke is a rare skin disease characterized by skin thickening and tightening typically at the neck and the upper part of the body. This thickening results from increased mucin deposition in the reticular dermis. Three variants are recognized. Scleredema diabeticorum is one subtype associated with diabetes mellitus. We report a man with a history of poorly controlled diabetes presenting with extensive scleredema adultorum of the trunk in a "cuirasse" pattern associated with restrictive lung disease. Cutaneous ultrasonography revealed a marked thickening of the dermis as well as various echogenic spots in the dermis. Cutaneous hardness secondary to scleredema may cause limited mobility. Therefore, respiratory manifestations may be associated and assessed, mainly in cases of extensive scleredema involving trunk and shoulders. Moreover, cutaneous ultrasonography may be useful to monitor the evolution of scleredema and confirm the diagnosis.


Subject(s)
Diabetes Complications/pathology , Respiration Disorders/etiology , Scleredema Adultorum/complications , Scleredema Adultorum/pathology , Humans , Male , Middle Aged , Scleredema Adultorum/diagnostic imaging , Torso/pathology , Ultrasonography
2.
Reumatol. clín. (Barc.) ; 10(5): 328-330, sept.-oct. 2014. ilus
Article in Spanish | IBECS | ID: ibc-126764

ABSTRACT

Si bien la neumonitis por hipersensibilidad es la complicación pulmonar más frecuentemente descrita durante el tratamiento con metotrexato, existen otras complicaciones de tipo linfoproliferativo e infeccioso que hay que tener en cuenta dentro del diagnóstico diferencial ante una neumopatía en el contexto de dicho tratamiento. La existencia de un riesgo incrementado de desarrollar procesos infecciosos o reactivaciones de microorganismos latentes puede ser similar al observado a lo largo del tratamiento con antagonistas del factor de necrosis tumoral y corticoides. Dentro de ellas, la neumonía por citomegalovirus es una complicación muy severa a tener en cuenta, ya que el diagnóstico acertado y el tratamiento oportuno evitarán un desenlace potencialmente mortal (AU)


Although hypersensitivity pneumonitis is the most common pulmonary complication described during treatment with methotrexate, other complications like lymphoproliferative and infectious disease may be considered in the study of respiratory disease associated to methotrexate. The existence of an increased risk to developing infectious diseases may be similar to that observed during treatment with antagonists of tumor necrosis factor and corticosteroids, where Cytomegalovirus pneumonia is a serious complication; early diagnosis and treatment will prevent a potentially fatal outcome (AU)


Subject(s)
Humans , Female , Aged, 80 and over , Pneumonia/complications , Pneumonia/diagnosis , Pneumonia/drug therapy , Methotrexate/pharmacokinetics , Methotrexate/therapeutic use , Alveolitis, Extrinsic Allergic/complications , Alveolitis, Extrinsic Allergic/diagnosis , Diagnosis, Differential , Alveolitis, Extrinsic Allergic/drug therapy , Alveolitis, Extrinsic Allergic/etiology , Alveolitis, Extrinsic Allergic/physiopathology , Radiography, Thoracic/methods , Radiography, Thoracic , Opportunistic Infections/complications
3.
Reumatol Clin ; 10(5): 328-30, 2014.
Article in English | MEDLINE | ID: mdl-24646908

ABSTRACT

Although hypersensitivity pneumonitis is the most common pulmonary complication described during treatment with methotrexate, other complications like lymphoproliferative and infectious disease may be considered in the study of respiratory disease associated to methotrexate. The existence of an increased risk to developing infectious diseases may be similar to that observed during treatment with antagonists of tumor necrosis factor and corticosteroids, where Cytomegalovirus pneumonia is a serious complication; early diagnosis and treatment will prevent a potentially fatal outcome.


Subject(s)
Antirheumatic Agents/adverse effects , Cytomegalovirus Infections/chemically induced , Methotrexate/adverse effects , Pneumonia, Viral/virology , Aged, 80 and over , Female , Humans
4.
Arch. bronconeumol. (Ed. impr.) ; 48(12): 479-481, dic. 2012. ilus
Article in Spanish | IBECS | ID: ibc-107740

ABSTRACT

La linfangioleiomiomatosis (LAM) es una enfermedad rara caracterizada por la proliferación anormal de células musculares lisas inmaduras y una destrucción quística del pulmón, que condiciona el pronóstico de la enfermedad. Los angiomiolipomas renales suelen ser muy frecuentes en esta enfermedad, generalmente de curso asintomático, salvo complicaciones. Ante la ausencia de un tratamiento curativo, las últimas publicaciones reflejan resultados esperanzadores en la terapia molecular para evitar el deterioro funcional y el control del tamaño de los angiomiolipomas. Entre estas terapias destacan los inhibidores del complejo mTOR, sobre todo sirolimus. Presentamos un caso clínico de una paciente diagnosticada de LAM sometida a trasplante pulmonar con reducción del tamaño del angiomiolipoma renal tras el tratamiento con el inhibidor mTOR everolimus(AU)


Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal proliferation of immature smooth muscle cells and cystic lung destruction, which determines the prognosis of the disease. The kidney angiomyolipomas are usually very common in this disease and are usually asymptomatic unless complications arise. In the absence of a curative treatment, recent publications show promising results in molecular therapy to prevent functional decline and to control the size of the angiomyolipomas. These therapies include mTOR complex inhibitors, especially sirolimus. We report a case of a patient diagnosed with LAM who underwent lung transplantation with reduction of renal angiomyolipoma size after treatment with the mTOR inhibitor everolimus(AU)


Subject(s)
Humans , Female , Adult , Angiomyolipoma/drug therapy , Kidney Neoplasms/drug therapy , TOR Serine-Threonine Kinases/antagonists & inhibitors , Lymphangioleiomyomatosis/complications , Angiomyolipoma/complications , Kidney Neoplasms/complications , TOR Serine-Threonine Kinases/pharmacology , Molecular Targeted Therapy , Lung Transplantation
5.
Arch Bronconeumol ; 48(12): 479-81, 2012 Dec.
Article in English, Spanish | MEDLINE | ID: mdl-22444789

ABSTRACT

Lymphangioleiomyomatosis (LAM) is a rare disease characterized by abnormal proliferation of immature smooth muscle cells and cystic lung destruction, which determines the prognosis of the disease. The kidney angiomyolipomas are usually very common in this disease and are usually asymptomatic unless complications arise. In the absence of a curative treatment, recent publications show promising results in molecular therapy to prevent functional decline and to control the size of the angiomyolipomas. These therapies include mTOR complex inhibitors, especially sirolimus. We report a case of a patient diagnosed with LAM who underwent lung transplantation with reduction of renal angiomyolipoma size after treatment with the mTOR inhibitor everolimus.


Subject(s)
Angiomyolipoma/drug therapy , Antineoplastic Agents/therapeutic use , Kidney Neoplasms/drug therapy , Kidney Neoplasms/pathology , Lung Transplantation , Lymphangioleiomyomatosis/surgery , Sirolimus/analogs & derivatives , Adult , Angiomyolipoma/complications , Angiomyolipoma/pathology , Everolimus , Female , Humans , Kidney Neoplasms/complications , Lymphangioleiomyomatosis/complications , Sirolimus/therapeutic use , Tumor Burden
6.
Intern Med ; 51(4): 363-8, 2012.
Article in English | MEDLINE | ID: mdl-22333370

ABSTRACT

OBJECTIVE: To evaluate the impact of oxidative stress and cellular adhesion molecules on ischemic reactive hyperemia (IRH) in patients with OSA. MATERIALS AND METHODS: Consecutive patients treated at a sleep laboratory and whose polysomnography showed an apnea hypopnea index (AHI) ≥5 were included in the study. Patients with acute illness receiving vasoactive medications were excluded. Based on their oxygen desaturation index (ODI), subjects were assigned to the mild-moderate (ODI ≤30) or the severe desaturation group (ODI >30). Then IRH and oxidative stress markers [malondialdehyde (MDA)] and proinflammatory markers (ICAM-1 and P-selectin) were measured. RESULTS: Sixty-eight subjects with OSA were included, 31 in the mild-moderate desaturation group and 37 in the severe group. No differences by age, gender and body mass index were observed. The severe desaturation group showed significantly higher values in the AHI, MDA, ICAM-1 and P-selectin (p<0.005), as well as a worsening of IRH (p=0.001). Only ICAM-1 (p=0.019) and P-selectin (p=0.033) were independently associated with IRH in a multiple-linear regression model. CONCLUSION: Patients with OSA and greater intermittent hypoxia showed worse endothelial function, and higher levels of MDA, ICAM-1 and P-selectin. Nevertheless, ICAM-1 and P-selectin rather than MDA were independently associated with IRH.


Subject(s)
Cell Adhesion Molecules/physiology , Endothelial Cells/physiology , Hyperemia/physiopathology , Oxidative Stress/physiology , Sleep Apnea, Obstructive/physiopathology , Adult , Aged , Atherosclerosis , Biomarkers/blood , Body Mass Index , Cell Adhesion Molecules/blood , Female , Humans , Intercellular Adhesion Molecule-1/blood , Laser-Doppler Flowmetry , Male , Malondialdehyde/blood , Middle Aged , P-Selectin/blood , Polysomnography , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...